These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11474669)

  • 1. New treatments for psoriasis.
    Granstein RD
    N Engl J Med; 2001 Jul; 345(4):284-7. PubMed ID: 11474669
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
    Ellis CN; Krueger GG;
    N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of alefacept in the treatment of psoriasis.
    Wong VK; Lebwohl M
    Skin Therapy Lett; 2003 Sep; 8(6):1-2, 7. PubMed ID: 14610613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
    Chamian F; Lin SL; Lee E; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG; Lowes MA
    J Transl Med; 2007 Jun; 5():27. PubMed ID: 17555598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alefacept for chronic plaque psoriasis: a selective therapy with long-lasting disease remissions and an encouraging safety profile.
    Leone G; Rolston K; Spaulding G
    Dermatol Nurs; 2003 Jun; 15(3):216-20, 224-5; quiz 226. PubMed ID: 12875010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic targets in psoriasis.
    Kupper TS
    N Engl J Med; 2003 Nov; 349(21):1987-90. PubMed ID: 14627782
    [No Abstract]   [Full Text] [Related]  

  • 7. [Targeted against T-cells: immunomodulators in psoriasis].
    Mader U
    Dtsch Med Wochenschr; 2003 Aug; 128(31-32):1640. PubMed ID: 12931726
    [No Abstract]   [Full Text] [Related]  

  • 8. Biologic therapy for psoriasis: the new therapeutic frontier.
    Singri P; West DP; Gordon KB
    Arch Dermatol; 2002 May; 138(5):657-63. PubMed ID: 12020229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest.
    Lamberg L
    JAMA; 2003 Jun; 289(21):2779-80, 2783. PubMed ID: 12783895
    [No Abstract]   [Full Text] [Related]  

  • 10. The 'heartbreak of psoriasis' has met its match!
    Morrow T
    Manag Care; 2003 Jun; 12(6):13, 17-8. PubMed ID: 12854254
    [No Abstract]   [Full Text] [Related]  

  • 11. Psoriasis and the new biologic agents: interrupting a T-AP dance.
    Walsh SR; Shear NH
    CMAJ; 2004 Jun; 170(13):1933-41. PubMed ID: 15210644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interleukin-4: a new option in the therapy of systemic psoriasis?].
    Homey B
    Hautarzt; 2003 Oct; 54(10):1019-20. PubMed ID: 14577420
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis of psoriasis and current challenges.
    Gupta AK; Langley R; Poulin Y; Lui H; Searles G; Carey W; Toole J; Inniss K
    J Cutan Med Surg; 2004 Aug; 8 Suppl():3-7. PubMed ID: 15655583
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of moderate to severe plaque psoriasis with biologic therapy.
    Pariser DM
    Manag Care; 2003 Apr; 12(4):36-44. PubMed ID: 12747028
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
    Larsen R; Ryder LP; Svejgaard A; Gniadecki R
    Clin Exp Immunol; 2007 Jul; 149(1):23-30. PubMed ID: 17403057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological agents and psoriatic epidermis: what are we ultimately targeting?
    Heenen M; Simonart T
    Dermatology; 2006; 212(4):321-3. PubMed ID: 16707880
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical update on alefacept: consideration for use in patients with psoriasis.
    Gade JN
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alefacept (Amevive) for treatment of psoriasis.
    Med Lett Drugs Ther; 2003 Apr; 45(1154):31-2. PubMed ID: 12717339
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Tutrone WD
    Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.